Drug
NMDAE plus Placebo Cap
NMDAE plus Placebo Cap is a pharmaceutical drug with 3 clinical trials. Currently 3 active trials ongoing.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
3(100%)
Phase Distribution
Ph phase_2
3
100%
Phase Distribution
0
Early Stage
3
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
3(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
3
trials recruiting
Total Trials
3
all time
Status Distribution
Active(3)
Detailed Status
Recruiting3
Development Timeline
Analytics
Development Status
Total Trials
3
Active
3
Success Rate
N/A
Most Advanced
Phase 2
Trials by Phase
Phase 23 (100.0%)
Trials by Status
recruiting3100%
Recent Activity
3 active trials
Showing 3 of 3
recruitingphase_2
Combination of NMDA-enhancing and Anti-inflammatory Treatments for Ultra-resistant Schizophrenia
NCT05240976
recruitingphase_2
Combination of NMDA-enhancing and Anti-inflammatory Treatments for Schizophrenia
NCT04917302
recruitingphase_2
Combination of NMDA-enhancing and Antioxidant Treatments for Schizophrenia
NCT04959201
Clinical Trials (3)
Showing 3 of 3 trials
NCT05240976Phase 2
Combination of NMDA-enhancing and Anti-inflammatory Treatments for Ultra-resistant Schizophrenia
NCT04917302Phase 2
Combination of NMDA-enhancing and Anti-inflammatory Treatments for Schizophrenia
NCT04959201Phase 2
Combination of NMDA-enhancing and Antioxidant Treatments for Schizophrenia
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3